TNYA
Tenaya Therapeutics, Inc.Healthcare · $132M market cap
Verdict
We can't put a fair value on TNYA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow TNYA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 10, 2026: no open-market purchases and 4 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works